Search Results - "Crane, C.H"

NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937) by Dawson, L.A., Winter, K., Knox, J., Zhu, A.X., Krishnan, S., Guha, C., Kachnic, L.A., Gillin, M.T., Hong, T.S., Craig, T., Hosni, A., Chen, E., Noonan, A., Koay, E.J., Sinha, R., Lock, M.I., Ohri, N., Dorth, J.A., Moughan, J., Crane, C.H.

“…The role of SBRT in the treatment of HCC is not well established. The hypothesis of this study was that overall survival (OS) would improve with SBRT followed…”
Get full text

Interobserver Variability in Target Definition for Hepatocellular Carcinoma (HCC) With and Without Portal Vein Thrombus: Radiation Therapy Oncology Group (RTOG) HCC Consensus Panel by Hong, T.S, Bosch, W.R, Crane, C.H, Dawson, L.A

Get full text

Duodenal Dose Sparing With Varying Stomach Volume During IG-IMRT Treatment by Suh, Y, Swanick, C.W, Beddar, S, Crane, C.H

Get full text

Paclitaxel-Based Chemoradiotherapy in Localized Gastric Carcinoma: Degree of Pathologic Response and Not Clinical Parameters Dictated Patient Outcome by AJANI, J. A, MANSFIELD, P. F, NIVERS, R, MORRIS, J, PISTERS, P. W, CRANE, C. H, WU, T. T, LUNAGOMEZ, S, LYNCH, P. M, JANJAN, N, FEIG, B, FAUST, J, YAO, J. C

“…Preoperative chemoradiotherapy may increase the R0 (curative) resection rate, overall survival (OS) duration, and disease-free survival (DFS) duration. We…”
Get full text

Outcomes of Patients With Hepatocellular Carcinoma and Advanced Cirrhosis After High-Dose Radiation Therapy Guided by Functional Liver Imaging With Tc99m Sulfur Colloid Liver SPECT-CT by Logan, J.K, Park, P.C, Wong, F.C, Erwin, W.D, Beddar, S, Kaseb, A.O, Crane, C.H, Koay, E.J

Get full text

Circulating Lymphocyte Count During Neoadjuvant Chemoradiation Therapy for Esophageal Cancer as a Predictive Biomarker of Pathologic Complete Response by Jiang, W, Davuluri, R, Fang, P, Xu, C, Welsh, J.W, Crane, C.H, Komaki, R.U, Cox, J.D, Hsu, C.C, Lin, S.H

Get full text

Immune Profile-to-Lymphocyte Ratios During Chemoradiation are Predictors of Clinical Outcomes in Esophageal Cancer by Fang, P, Jiang, W, Davuluri, R, Xu, C, Welsh, J.W, Komaki, R.U, Crane, C.H, Hsu, C.C, Lin, S.H

Get full text

Absolute Lymphocyte Count Nadir During Chemoradiation as a Prognostic Indicator of Esophageal Cancer Survival Outcomes by Davuluri, R, Jiang, W, Fang, P, Xu, C, Komaki, R.U, Hsu, C.C, Lin, S.H, Welsh, J.W, Cox, J.D, Crane, C.H

Get full text

Quantitative European Association for the Study of the Liver (qEASL) as an Early Biomarker of Response After Radiation Therapy for Intrahepatic Cholangiocarcinoma by Amer, A.M, Tao, R, Kang, H, Chun, Y, Vauthey, J.N, Javle, M.M, Kaseb, A.O, Crane, C.H, Koay, E.J

Get full text

A Computed Tomography Imaging Feature of Pancreatic Cancer As a Predictive Biomarker for Escalated Dose Radiation Therapy by Moningi, S, Amer, A, Colbert, L.E, Lee, Y, Hall, W.A, Erickson, B.A, Varadhachary, G.R, Das, P, Taniguchi, C.M, Fleming, J.B, Katz, M, Crane, C.H, Koay, E.J

Get full text

Change in Platelet Count and Normal Liver Dosimetry in Patients Receiving Proton Radiation Therapy for Unresectable Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma by Dyer, M.A, McDonnell, E.I, Yeap, B.Y, Depauw, N, Wolfgang, J.A, Wo, J.Y, DeLaney, T.F, Ben-Josef, E, Crane, C.H, Zhu, A.X, Hong, T.I

Get full text

Dose Escalation With an Intensity Modulated Radiation Therapy Technique in 15 to 28 Fractions Is Better Tolerated Than Are Standard Doses of 3DCRT for LAPC by Colbert, L.E, Moningi, S, Chadha, A.S, Wolff, R.A, Varadhachary, G.R, Fleming, J.B, Katz, M, Taniguchi, C.M, Das, P, Krishnan, S, Koay, E.J, Crane, C.H

Get full text

Outcomes Following Hyperfractionated Accelerated Reirradiation for Recurrent Anal Cancer by Osborne, E.M, Eng, C, Skibber, J, Rodriguez-Bigas, M, Chang, G, You, Y.N, Bednarski, B, Minsky, B.D, Delclos, M.E, Koay, E.J, Krishnan, S, Crane, C.H, Das, P

Get full text

Hyperfractionated Accelerated Reirradiation for Rectal Cancer: A Large Single-Institution Retrospective Analysis by Tao, R, Tsai, C.J, Eng, C, Kopetz, S, Overman, M, Skibber, J, Rodriguez-Bigas, M, Chang, G, You, Y.N, Bednarski, B, Minsky, B.D, Delclos, M.E, Koay, E.J, Krishnan, S, Crane, C.H, Das, P

Get full text

Proton Therapy Outcomes for Localized, Unresectable Hepatocellular Carcinoma by Chadha, A.S, Gunther, J.R, Minsky, B.D, Taniguchi, C.M, Mahmood, U, Delclos, M.E, Suh, Y, Sawakuchi, G.O, Park, P.C, Beddar, S, Gupta, S, Kaur, H, Javle, M.M, Kaseb, A.O, Koay, E.J, Das, P, Crane, C.H, Krishnan, S

Get full text

Incidence and Predictors of Chest Wall Toxicity After High Dose Radiation Therapy in 15 Fractions by Swanick, C.W, Allen, P.K, Tao, R, Olanrewaju, A.M, Sutton, J.R, Lin, S.H, Welsh, J.W, Das, P, Chang, J.Y, Crane, C.H, Gomez, D.R

Get full text

Ablative Radiation Therapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma by Tao, R, Krishnan, S, Bhosale, P, Javle, M, Shroff, R, Kaseb, A, Jensen, G, Bishop, A.J, Swanick, C.W, Koay, E.J, Thames, H.D, Hong, T.S, Das, P, Crane, C.H

Get full text

Prospective and Concurrent Analysis of Postresection CA19-9 Level and Surgical Margin Status (SMS) as Predictors of Pattern of Disease Recurrence Following Adjuvant Treatment for Pancreatic Carcinoma: NRG Oncology/RTOG 9704 Secondary Analysis by Regine, W.F, Winter, K, Kessel, I.L, Chen, Y, Fugazzi, J.A, Donnelly, E.D, DiPetrillo, T.A, Narayan, S, Plastaras, J.P, Gaur, R, Delouya, G, Suh, J.H, Meyer, J.E, Haddock, M.G, Didolkar, M.S, Padula, G.D.A, Johnson, D.B, Hoffman, J.P, Crane, C.H

Get full text

Biologic Mesh Spacer Placement Facilitates Safe Delivery of Dose-intense Radiation Therapy: A Novel Treatment Option for Unresectable Liver Tumors by Ismael, Hishaam Nabil, MD, FACS, Denbo, Jason, MD, Cox, Steven, MD, Crane, Christopher H., MD, Das, Prajnan, MD, Krishnan, Sunil, MD, Schroff, Rashna T., MD, Javle, Milind, MD, Conrad, Claudius, MD, Vauthey, Jean-Nicolas, MD, Aloia, Thomas, MD

“…Abstract Introduction Patients with unresectable liver tumors who fail initial treatment modalities have a poor prognosis (<1 yr). Although effective, delivery…”
Get full text

Quality of Life After Intensity Modulated Radiation Therapy (IMRT) for Anal Cancer by Tang, Y, Crane, C.H, Eng, C, Minsky, B.D, Delclos, M.E, Krishnan, S, Malatek, D.L, Gould, S.S, Prajnan, D

Get full text